Artificial intelligence-based biotechnology company Noetik announced a five-year strategic collaboration and AI model licensing agreement with UK pharmaceutical giant GSK. This collaboration focuses on the fields of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). GSK will obtain non-exclusive access to Noetik's self-developed OCTO-VC virtual cell foundational model to accelerate the oncology drug development process.

According to the agreement, Noetik's OCTO-VC model will serve as a core technological tool to support GSK's Artificial Intelligence & Therapeutics team in oncology drug target discovery and validation. This model, by integrating self-supervised machine learning with high-throughput spatial omics data, can simulate the dynamic changes of human cells within the tumor microenvironment, providing a biological simulation platform that is closer to physiological conditions for oncology drug development.

The collaborating parties will also jointly develop customized human spatial datasets to further enhance the predictive capabilities of the virtual cell model.